JP2019519583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519583A5 JP2019519583A5 JP2018568716A JP2018568716A JP2019519583A5 JP 2019519583 A5 JP2019519583 A5 JP 2019519583A5 JP 2018568716 A JP2018568716 A JP 2018568716A JP 2018568716 A JP2018568716 A JP 2018568716A JP 2019519583 A5 JP2019519583 A5 JP 2019519583A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- oxide
- compound
- group
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, hydroxy Chemical group 0.000 claims 27
- 150000001204 N-oxides Chemical class 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- DTCZNKWBDTXEBS-UHFFFAOYSA-N CC1=CC(=C2C(=N1)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)(F)F)=O)C Chemical compound CC1=CC(=C2C(=N1)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)(F)F)=O)C DTCZNKWBDTXEBS-UHFFFAOYSA-N 0.000 claims 1
- RJQGPVBHMYZOSM-UHFFFAOYSA-N CC1=CC(=C2C(=N1)CN(C2)C(CC1CN(C1)C=1C=NC=CC=1)=O)C Chemical compound CC1=CC(=C2C(=N1)CN(C2)C(CC1CN(C1)C=1C=NC=CC=1)=O)C RJQGPVBHMYZOSM-UHFFFAOYSA-N 0.000 claims 1
- OTUOXGZVIWSELJ-UHFFFAOYSA-N COCC1=CC(=C2C(=N1)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)(F)F)=O)C Chemical compound COCC1=CC(=C2C(=N1)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)(F)F)=O)C OTUOXGZVIWSELJ-UHFFFAOYSA-N 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- KAADPUKOZSAOGP-UHFFFAOYSA-N ClC=1C(=C2C(=NC=1C)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)F)=O)C Chemical compound ClC=1C(=C2C(=NC=1C)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)F)=O)C KAADPUKOZSAOGP-UHFFFAOYSA-N 0.000 claims 1
- YHMUPFLHJYDUGF-UHFFFAOYSA-N ClC=1C(=C2C(=NC=1COC)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)F)=O)C Chemical compound ClC=1C(=C2C(=NC=1COC)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)F)=O)C YHMUPFLHJYDUGF-UHFFFAOYSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- YJVGDXXALNHHDY-UHFFFAOYSA-N OCC1=CC(=C2C(=N1)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)(F)F)=O)C Chemical compound OCC1=CC(=C2C(=N1)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C(F)(F)F)=O)C YJVGDXXALNHHDY-UHFFFAOYSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 125000005879 dioxolanyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357624P | 2016-07-01 | 2016-07-01 | |
| US62/357,624 | 2016-07-01 | ||
| US201662372421P | 2016-08-09 | 2016-08-09 | |
| US62/372,421 | 2016-08-09 | ||
| PCT/IB2017/053565 WO2018002760A1 (en) | 2016-07-01 | 2017-06-15 | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519583A JP2019519583A (ja) | 2019-07-11 |
| JP2019519583A5 true JP2019519583A5 (OSRAM) | 2020-07-27 |
| JP7046018B2 JP7046018B2 (ja) | 2022-04-01 |
Family
ID=59215839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568716A Active JP7046018B2 (ja) | 2016-07-01 | 2017-06-15 | 神経性疾患および神経変性疾患を処置するための５，７－ジヒドロピロロピリジン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10604519B2 (OSRAM) |
| EP (2) | EP3478679B1 (OSRAM) |
| JP (1) | JP7046018B2 (OSRAM) |
| KR (1) | KR102470497B1 (OSRAM) |
| CN (1) | CN109641898B (OSRAM) |
| AU (1) | AU2017286868B2 (OSRAM) |
| CA (1) | CA2972070A1 (OSRAM) |
| DK (1) | DK3478679T3 (OSRAM) |
| ES (1) | ES2878160T3 (OSRAM) |
| HU (1) | HUE054857T2 (OSRAM) |
| IL (1) | IL263912B (OSRAM) |
| MX (1) | MX386258B (OSRAM) |
| PH (1) | PH12019500004A1 (OSRAM) |
| PL (1) | PL3478679T3 (OSRAM) |
| PT (1) | PT3478679T (OSRAM) |
| SG (1) | SG11201811712QA (OSRAM) |
| TW (1) | TWI736642B (OSRAM) |
| UY (1) | UY37311A (OSRAM) |
| WO (1) | WO2018002760A1 (OSRAM) |
| ZA (1) | ZA201900519B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018226545A1 (en) * | 2017-06-09 | 2018-12-13 | Merck Sharp & Dohme Corp. | Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor |
| ES2937236T3 (es) * | 2017-06-22 | 2023-03-27 | Pfizer | Derivados de dihidro-pirrolo-piridina |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| JP7646653B2 (ja) * | 2019-11-22 | 2025-03-17 | エフ． ホフマン－ラ ロシュ アーゲー | ピロリジン誘導体 |
| KR20250057919A (ko) * | 2020-04-29 | 2025-04-29 | 릴레이 테라퓨틱스, 인크. | PI3Kα 억제제 및 이의 사용 방법 |
| CN112174869B (zh) * | 2020-10-12 | 2023-04-25 | 蔡霈 | N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途 |
| EP4236928A4 (en) * | 2020-10-30 | 2024-08-28 | 1Cbio, Inc. | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND THEIR USES |
| US20220354862A1 (en) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Liposome delivery of psychedelics |
| JP2025530462A (ja) | 2022-09-23 | 2025-09-11 | セレベル・セラピューティクス・エル・エル・シー | エムラクリジンの結晶形態、その調製方法及びその使用 |
| TW202432557A (zh) * | 2022-10-28 | 2024-08-16 | 大陸商紐歐申醫藥（上海）有限公司 | 一種含氮雜環化合物、其藥學上可接受的鹽及其製備方法與應用 |
| CN120641414A (zh) * | 2022-12-16 | 2025-09-12 | 卡鲁娜治疗学有限公司 | 经取代的四氢吡咯并-吡啶酮化合物及其在治疗医学病状中的用途 |
| WO2024130065A1 (en) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions |
| EP4634194A1 (en) * | 2022-12-16 | 2025-10-22 | Karuna Therapeutics, Inc. | Substituted dihydropyrrolo [3, 4-d] pyrimidine compounds and their use in treating medical conditions |
| AU2023398924A1 (en) * | 2022-12-16 | 2025-06-26 | Karuna Therapeutics, Inc. | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions |
| WO2024230794A1 (zh) * | 2023-05-11 | 2024-11-14 | 中国药科大学 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| CN116693437A (zh) * | 2023-06-15 | 2023-09-05 | 安徽大学 | 一种N-Boc-3-氮杂环丁烷乙酸的合成方法 |
| WO2024260386A1 (zh) * | 2023-06-20 | 2024-12-26 | 西藏海思科制药有限公司 | 毒蕈碱m4受体激动剂及其用途 |
| WO2025055965A1 (zh) * | 2023-09-13 | 2025-03-20 | 中国药科大学 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| WO2025055970A1 (zh) * | 2023-09-15 | 2025-03-20 | 江苏恩华药业股份有限公司 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| WO2025083630A1 (en) | 2023-10-19 | 2025-04-24 | Suven Life Sciences Limited | Heteroaromatic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2025099660A1 (en) | 2023-11-10 | 2025-05-15 | Suven Life Sciences Limited | Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2025103475A1 (zh) * | 2023-11-17 | 2025-05-22 | 上海翰森生物医药科技有限公司 | 杂环羰基类衍生物调节剂、其制备方法和应用 |
| WO2025122811A1 (en) * | 2023-12-07 | 2025-06-12 | Acadia Pharmaceuticals Inc. | M4 positive allosteric modulators |
| WO2025131049A1 (en) * | 2023-12-21 | 2025-06-26 | Ignis Therapeutics (Suzhou) Limited | Dihydro-pyrrolo-pyridine derivatives and uses thereof |
| WO2025134078A1 (en) | 2023-12-22 | 2025-06-26 | Suven Life Sciences Limited | Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| TW202525292A (zh) * | 2023-12-27 | 2025-07-01 | 大陸商宜昌人福藥業有限責任公司 | 稠合嘧啶環化合物、藥物組合物及其應用 |
| WO2025145091A1 (en) | 2023-12-29 | 2025-07-03 | Pfizer Inc. | Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases |
| WO2025201078A1 (zh) * | 2024-03-25 | 2025-10-02 | 四川科伦药物研究院有限公司 | 化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017197A1 (fr) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| EP2305709A1 (en) | 1997-04-09 | 2011-04-06 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| KR100767146B1 (ko) | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| NZ544691A (en) | 2000-11-03 | 2007-12-21 | Proteotech Inc | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
| US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| MXPA05003621A (es) | 2002-10-09 | 2005-10-19 | Rinat Neuroscience Corp | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| JP2006527756A (ja) | 2003-06-19 | 2006-12-07 | ファイザー・プロダクツ・インク | Ｎｋ１拮抗薬 |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| CA2555071A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| EP1807434B1 (en) | 2004-10-25 | 2010-08-25 | Eli Lilly And Company | Thienopyridines as allosteric potentiators of the m4 muscarinic receptor |
| WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| BRPI0609225A2 (pt) | 2005-05-12 | 2010-03-09 | Pfizer | formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| CA2603830A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | PYRIDINE [2,3-B] PYRAZINONES |
| WO2006136924A1 (en) | 2005-06-22 | 2006-12-28 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
| TW200713011A (en) | 2005-09-30 | 2007-04-01 | Hon Hai Prec Ind Co Ltd | System, method and electrical apparatus for data transferring |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
| SI2013208T1 (sl) | 2006-04-21 | 2011-09-30 | Pfizer Prod Inc | Piridin(3,4-b)pirazinoni |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| CN1869036A (zh) * | 2006-06-30 | 2006-11-29 | 中国药科大学 | 7－取代－3－氯吡咯并[3,4－b]吡啶化合物 |
| EP2124933B1 (en) | 2007-01-22 | 2012-10-17 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| US8664234B2 (en) | 2010-10-04 | 2014-03-04 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators |
| AR083855A1 (es) * | 2010-11-15 | 2013-03-27 | Abbott Lab | Inhibidores de nampt y rock |
| WO2012138845A1 (en) * | 2011-04-08 | 2012-10-11 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| JP6240063B2 (ja) * | 2011-04-28 | 2017-11-29 | ザ ブロード インスティテュート， インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| EP2780337B1 (en) * | 2011-11-15 | 2017-12-20 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| US8741892B2 (en) * | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
| US8642774B2 (en) * | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
| EP3321257A1 (en) | 2012-02-23 | 2018-05-16 | Vanderbilt University | Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| WO2014035829A1 (en) * | 2012-08-31 | 2014-03-06 | Vanderbilt University | Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators |
| US20160200733A1 (en) | 2013-08-23 | 2016-07-14 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| US9637498B2 (en) * | 2013-08-23 | 2017-05-02 | Vanderbilt University | Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| US11497586B2 (en) | 2014-03-21 | 2022-11-15 | Align Technology, Inc. | Segmented orthodontic appliance with elastics |
| SMT202400446T1 (it) * | 2014-02-06 | 2024-11-15 | Nxera Pharma Uk Ltd | Composti aza biciclici come agonisti del recettore muscarinico |
-
2017
- 2017-06-15 EP EP17733044.6A patent/EP3478679B1/en active Active
- 2017-06-15 ES ES17733044T patent/ES2878160T3/es active Active
- 2017-06-15 PL PL17733044T patent/PL3478679T3/pl unknown
- 2017-06-15 CN CN201780053245.2A patent/CN109641898B/zh active Active
- 2017-06-15 HU HUE17733044A patent/HUE054857T2/hu unknown
- 2017-06-15 PT PT177330446T patent/PT3478679T/pt unknown
- 2017-06-15 DK DK17733044.6T patent/DK3478679T3/da active
- 2017-06-15 SG SG11201811712QA patent/SG11201811712QA/en unknown
- 2017-06-15 EP EP21167379.3A patent/EP3872078A1/en active Pending
- 2017-06-15 KR KR1020197002851A patent/KR102470497B1/ko active Active
- 2017-06-15 AU AU2017286868A patent/AU2017286868B2/en active Active
- 2017-06-15 JP JP2018568716A patent/JP7046018B2/ja active Active
- 2017-06-15 MX MX2019000231A patent/MX386258B/es unknown
- 2017-06-15 WO PCT/IB2017/053565 patent/WO2018002760A1/en not_active Ceased
- 2017-06-28 TW TW106121650A patent/TWI736642B/zh active
- 2017-06-28 CA CA2972070A patent/CA2972070A1/en active Pending
- 2017-06-29 US US15/637,071 patent/US10604519B2/en active Active
- 2017-06-30 UY UY0001037311A patent/UY37311A/es not_active Application Discontinuation
-
2018
- 2018-12-23 IL IL263912A patent/IL263912B/en unknown
-
2019
- 2019-01-03 PH PH12019500004A patent/PH12019500004A1/en unknown
- 2019-01-24 ZA ZA2019/00519A patent/ZA201900519B/en unknown
-
2020
- 2020-02-21 US US16/797,966 patent/US20200207762A1/en not_active Abandoned
-
2021
- 2021-06-01 US US17/335,666 patent/US11905284B2/en active Active
-
2023
- 2023-02-21 US US18/112,156 patent/US20230192690A1/en not_active Abandoned
- 2023-12-07 US US18/532,547 patent/US20240190869A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519583A5 (OSRAM) | ||
| JP2020524687A5 (OSRAM) | ||
| AU2016355710B2 (en) | Modulators of ROR-gamma | |
| AU2020374957A1 (en) | Small molecule degraders of Helios and methods of use | |
| AU2019293235B2 (en) | Immunomodulatory compounds | |
| AU2011343646A1 (en) | Inhibitors of influenza viruses replication | |
| US20090124635A1 (en) | Chemical compounds | |
| JP2015514794A (ja) | 新規化合物 | |
| CN102869661A (zh) | 抗感染化合物 | |
| JP2010513432A (ja) | インドリジン酢酸およびｃｒｔｈ２受容体のリガンドとしてのその治療的使用 | |
| JP6681517B2 (ja) | ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用 | |
| AU2010310518A1 (en) | mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| JP6893516B2 (ja) | ３−（（ヘテロ−）アリール）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体 | |
| RU2016110483A (ru) | Производные пирролопиридина или пиразолопиридина | |
| US20210230180A1 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 | |
| AU2014234906A1 (en) | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | |
| TW202116754A (zh) | 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑 | |
| US10870630B2 (en) | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors | |
| JP2019505558A5 (OSRAM) | ||
| US11198687B2 (en) | Heteroaryl allosteric modulators of nicotinic acetylcholine receptors | |
| US20120172347A1 (en) | 8-oxodihydropurine derivative | |
| JPWO2019183636A5 (OSRAM) | ||
| JP2009510162A5 (OSRAM) | ||
| US20210196734A1 (en) | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | |
| WO2023042914A1 (en) | Pyrrolidine compounds as histone deacetylase inhibitors |